KindredBio

Burlingame, United States Founded: 2012 • Age: 14 yrs Acquired By Elanco
Veterinary antibodies for cats, dogs, and horses are developed.
Annual revenue $42.2M Latest available
Total funding $6.9M 3 rounds
Employees 64 Tracked headcount
Investors 2 Known backers
Products - Services tracked
Competitors 9 Brand Intelligence

About KindredBio

KindredBio is a company based in Burlingame (United States) founded in 2012 was acquired by Elanco in June 2021. KindredBio has raised $6.9 million across 3 funding rounds from investors including Elanco and SLR Investment Corp. The company has 64 employees as of December 31, 2022. KindredBio operates in a competitive market with competitors including Zoetis, Ceva, PetMedix, QBiotics and Hester Biosciences, among others.

  • Headquarter Burlingame, United States
  • Employees 64 as on 31 Dec, 2022
  • Stage Public
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Kindred Biosciences, Inc.
Operational Areas
Healthcare → Veterinary & Animal Health Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $42.16 M (USD)
    891
    as on Dec 31, 2020
  • Net Profit
    -$21.8 M (USD)
    64
    as on Dec 31, 2020
  • EBITDA
    -$19.97 M (USD)
    68
    as on Dec 31, 2020
  • Total Equity Funding
    $6.9 M (USD)

    in 3 rounds

  • Latest Funding Round
    $50 M (USD), Debt – Conventional

    Oct 02, 2019

  • Investors
    Elanco

    & 1 more

  • Employee Count
    64

    as on Dec 31, 2022

  • Acquired by
    Elanco

    (Jun 16, 2021)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

People of KindredBio

Headcount 5000-10000
Employee Profiles 648
Board Members and Advisors 12
Employee Profiles
People
Mauricio Tessarini Lopes
Latam Senior Procurement Manager
People
Angela Billingsley
Quality Assurance Manager
People
Lisa McMorrow Casey
Senior IT Director
People
Jeffrey N. Simmons
President & CEO

Unlock access to complete

Board Members and Advisors
people
R. David Hoover
Chairman
people
Lawrence E. Kurzius
Director
people
John Bilbrey
Director
people
Art A. Garcia
Director

Unlock access to complete

Funding Insights of KindredBio

KindredBio has successfully raised a total of $6.9M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $50 million completed in October 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in KindredBio

KindredBio has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Elanco and SLR Investment Corp.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Debt and equity investments are offered by the firm.
Locked Locked Locked
Veterinary food and medicines products are provided for animal health.
Locked Locked Locked
Premium access

Investor details for KindredBio

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by KindredBio

Investments
Premium access

Investment portfolio details for KindredBio

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - KindredBio

Premium access

Detailed financials for KindredBio

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Kindredbio Comparisons

KindredBio Primary company
Description
Veterinary antibodies for cats, dogs, and horses are develop...
Location
Burlingame, United States
Founded Year
2012
Annual Revenue
$42.16 M (USD)
Net Profit
-$21.8 M (USD)
EBITDA
-$19.97 M (USD)
Employees
64
As of 2022
Premium access

Peer comparison for KindredBio

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of KindredBio

KindredBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Zoetis, Ceva, PetMedix, QBiotics and Hester Biosciences, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Animal medicines, vaccines, and diagnostics are manufactured and supplied.
Locked Locked Locked
Animal health therapeutics are developed and supplied globally by Ceva.
Locked Locked Locked
Developer of monoclonal antibody therapeutics for pets
Locked Locked Locked
Small molecules from plant extracts are developed for medical applications.
Locked Locked Locked
Manufacturer of animal vaccines and healthcare products
Locked Locked Locked
Biopharmaceuticals for animals are manufactured and supplied through partnerships.
Premium access

Detailed competitors of KindredBio

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Kindredbio

Premium access

Complete news archive for KindredBio

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about KindredBio

KindredBio was founded in 2012.

KindredBio is headquartered in Burlingame, United States. It is registered at Burlingame, California, United States.

KindredBio is a funded company, having raised a total of $6.9M across 3 funding rounds to date.

As of Dec 31, 2022, the latest employee count at KindredBio is 64.

Annual revenue of KindredBio is $42.16M as on Dec 31, 2020.

Kindred Biosciences was founded in 2012 and is headquartered in Burlingame, United States. Operations are centered on veterinary biotechnology, with a focus on antibody-based therapies for animal diseases. Treatments targeting conditions in cats, dogs, and horses have been developed by the company. Activities encompass research and development within the animal health sector, supporting therapeutic advancements for companion and equine species.

KindredBio's top competitors include Zoetis, Ceva and QBiotics.

KindredBio has 2 investors. Key investors include Elanco, and SLR Investment Corp.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available